Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

2(40.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04770272Phase 2Terminated

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Role: lead

NCT06655337Not ApplicableRecruiting

Efficiency of the "Medidux" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)

Role: collaborator

NCT05425550Not ApplicableTerminated

Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.

Role: lead

NCT05354973Recruiting

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy

Role: collaborator

NCT03272477Phase 2Completed

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Role: lead

NCT05234021Completed

HER2-directed Biosimilar in Breast Cancer: Real World ePRO

Role: collaborator

NCT03220178Phase 4Terminated

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Role: lead

All 7 trials loaded